Published in J Viral Hepat on March 01, 1999
Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. J Clin Microbiol (2000) 2.70
A genotype-independent real-time PCR assay for quantification of hepatitis B virus DNA. J Clin Microbiol (2006) 1.08
Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first- and second-generation assays. N Engl J Med (1991) 3.02
Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med (1992) 3.01
Antibody to hepatitis B surface antigen after a single inoculation of uncoupled synthetic HBsAg peptides. Nature (1982) 3.01
Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology (1996) 2.94
Dilution assay statistics. J Clin Microbiol (1994) 2.61
Treatment of arthritis with topical capsaicin: a double-blind trial. Clin Ther (1991) 2.44
Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology (1989) 2.39
Assay of Australia antigen and antibody employing double-antibody and solid-phase radioimmunoassay techniques and comparison with the passive hemagglutination methods. J Immunol (1971) 2.35
Detection of hepatitis A viral antigen by radioimmunoassay. J Immunol (1975) 2.33
Serum alanine aminotransferase of donors in relation to the risk of non-A,non-B hepatitis in recipients: the transfusion-transmitted viruses study. N Engl J Med (1981) 2.29
Sequence and analysis of chromosome 3 of the plant Arabidopsis thaliana. Nature (2000) 2.17
Multicenter evaluation of quantification methods for plasma human immunodeficiency virus type 1 RNA. J Infect Dis (1994) 2.15
Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology (2001) 2.13
Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J Gastroenterol Hepatol (2000) 2.06
Infectious liver diseases in three groups of Copenhagen workers: correlation of hepatitis A infection to sewage exposure. Arch Environ Health (1981) 2.03
Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients. An analysis of the Transfusion-Transmitted Viruses Study. Ann Intern Med (1984) 2.01
Establishment of a quality assurance program for human immunodeficiency virus type 1 DNA polymerase chain reaction assays by the AIDS Clinical Trials Group. ACTG PCR Working Group, and the ACTG PCR Virology Laboratories. J Clin Microbiol (1993) 1.85
Nonparenteral transmission of viral hepatitis type B (Australia antigen-associated serum hepatitis). N Engl J Med (1971) 1.84
Biophysical and biochemical heterogeneity of purified hepatitis B antigen. J Virol (1972) 1.70
Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology (1999) 1.59
Bleeding from a Meckel's diverticulum after the use of ibuprofen. Am J Gastroenterol (1992) 1.54
Infection of the retina by human immunodeficiency virus type I. N Engl J Med (1987) 1.50
Sebaceous carcinoma of the ocular adnexa: radiotherapeutic management. Int J Radiat Oncol Biol Phys (1989) 1.49
Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat (2000) 1.45
Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3. J Viral Hepat (2008) 1.45
Polyarthritis, polyarteritis and hepatitis B. Medicine (Baltimore) (1976) 1.44
Increased hepatocyte expression of hepatitis B virus transcription in patients with features of fibrosing cholestatic hepatitis. Gastroenterology (1993) 1.43
Antibodies to viral antigens in systemic lupus erythematosus. Arthritis Rheum (1971) 1.42
Production of potent anti-Australia antigen sera of high specificity and sensitivity in goats. Infect Immun (1972) 1.41
Nashville experience with liver transplantation in Veterans Administration patients. J Surg Res (1997) 1.39
Psychopharmacologic treatment of negative schizophrenic symptoms. Compr Psychiatry (1994) 1.39
Non-A, non-B hepatitis and antibody to hepatitis C virus. JAMA (1990) 1.37
A multicenter study of viral hepatitis in a United States hemophilic population. Blood (1993) 1.37
Cellular and humoral immunity in guinea pigs to two major polypeptides derived from hepatitis B surface antigen. J Gen Virol (1978) 1.37
Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection. BMJ (1993) 1.34
The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med (2001) 1.30
Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J Acquir Immune Defic Syndr (2001) 1.30
Twenty years of the German Environmental Survey (GerES): human biomonitoring--temporal and spatial (West Germany/East Germany) differences in population exposure. Int J Hyg Environ Health (2007) 1.30
Comparative biophysical studies of hepatitis B antigen, subtypes adw and ayw. J Virol (1975) 1.29
Donor screening for antibody to hepatitis B core antigen and hepatitis B virus infection in transfusion recipients. Transfusion (1995) 1.27
Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and Infants Transmission Study. J Infect Dis (1998) 1.26
Hepatitis B virus DNA in mononuclear cells and analysis of cell subsets for the presence of replicative intermediates of viral DNA. J Infect Dis (1986) 1.26
Evaluation of a multiplex PCR assay (Bruce-ladder) for molecular typing of all Brucella species, including the vaccine strains. J Clin Microbiol (2008) 1.25
Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. Hepatology (1997) 1.25
An ELISA for detection of antibodies to the E2 protein of GB virus C. J Infect Dis (1997) 1.24
Limitations of solid-phase radioimmunoassay for hb ag in reducing frequency of post-transfusion hepatitis. N Engl J Med (1973) 1.23
Hepatitis B vaccines--to switch or not to switch. JAMA (1987) 1.23
German health-related environmental monitoring: assessing time trends of the general population's exposure to heavy metals. Int J Hyg Environ Health (2013) 1.23
Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut (2006) 1.22
Hemifacial microsomia: progress in understanding the genetic basis of a complex malformation syndrome. Hum Genet (2001) 1.19
Improved methods for quantification of human immunodeficiency virus type 1 RNA and hepatitis C virus RNA in blood using spin column technology and chemiluminescent assays of PCR products. J Med Virol (1997) 1.19
Intra-assay performance characteristics of five assays for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (1998) 1.18
Detection of viral hepatitis type A. Am J Clin Pathol (1976) 1.17
Evidence for the presence of repeating antigenic determinants in the major polypeptides derived from hepatitis B surface antigen. Virology (1981) 1.17
Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology (1997) 1.17
Fusion as a mediator of cytolysis in mixtures of uninfected CD4+ lymphocytes and cells infected by human immunodeficiency virus. Proc Natl Acad Sci U S A (1987) 1.17
Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA. J Viral Hepat (1999) 1.16
The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor. Int J Immunopharmacol (1992) 1.16
High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis. Gastroenterology (1992) 1.12
Production of antibody to individual polypeptides derived from purified hepatitis B surface antigen. J Virol (1975) 1.12
Diagnosis of crystal-induced arthritis by synovial fluid examination for crystals: lessons from an imperfect test. Arthritis Care Res (1999) 1.11
Rapid resolution of chylous ascites after liver transplantation using somatostatin analog and total parenteral nutrition. Transplantation (1996) 1.11
Biophysical and biochemical properties of purified preparations of hepatitis B surface antigen (HBs Ag). Am J Med Sci (1976) 1.11
A multicenter clinical trial of oral ribavirin in HIV-infected people with lymphadenopathy: virologic observations. Ribavirin-LAS Collaborative Group. AIDS (1990) 1.10
Chronic viral hepatitis C: management update. CMAJ (2000) 1.10
Type B hepatitis antigen and antibody among prostitutes and nuns: a study of possible venereal transmission. J Infect Dis (1974) 1.09
Humoral and cellular immunity to hepatitis B virus-derived antigens: comparative activity of Freund complete adjuvant alum, and liposomes. Infect Immun (1980) 1.09
Immune response to hepaitis virus type B in Down's syndrome and other mentally retarded patients. Am J Epidemiol (1972) 1.07
Anti-HBs responses to vaccination with a human hepatitis B vaccine made by recombinant DNA technology in yeast. J Infect Dis (1986) 1.07
Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice. Aliment Pharmacol Ther (2006) 1.07
Extrachromosomal sequences of hepatitis B virus DNA in peripheral blood mononuclear cells of acquired immune deficiency syndrome patients. Proc Natl Acad Sci U S A (1986) 1.06
The epidemiology of St. Louis encephalitis in Dallas, Texas, 1966. Am J Epidemiol (1975) 1.05
Defining the time of fetal or perinatal acquisition of human immunodeficiency virus type 1 infection on the basis of age at first positive culture. Women and Infants Transmission Study (WITS). J Infect Dis (1997) 1.05
Isolation and characterization of hepatitis A virus. Am J Clin Pathol (1976) 1.04
Serotonin transporter function is modulated by brain-derived neurotrophic factor (BDNF) but not nerve growth factor (NGF). Neurochem Int (2000) 1.04
Cloning and characterization of a new member of the Nudix hydrolases from human and mouse. J Biol Chem (2000) 1.03
Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes. Hepatology (2000) 1.03
Polymerase chain reaction assay for hepatitis C virus RNA using a single tube for reverse transcription and serial rounds of amplification with nested primer pairs. J Med Virol (1992) 1.03
Cobalt plaque versus enucleation for uveal melanoma: comparison of survival rates. Br J Ophthalmol (1988) 1.02
Preliminary serologic studies of antibody to hepatitis A virus in populations in the United States. J Infect Dis (1976) 1.02
Diamminodichloroplatinum in the chemotherapy of testicular tumors. J Urol (1974) 1.02
A predictive model for the development of hepatocellular carcinoma, liver failure, or liver transplantation for patients presenting to clinic with chronic hepatitis C. Am J Gastroenterol (1999) 1.01
Non-A, non-B hepatitis transmission in chimpanzees: a project of the transfusion-transmitted viruses study group. Intervirology (1978) 1.00
Meconium ileus: is a stoma necessary? J Pediatr Surg (1986) 0.99
Occult hepatitis B virus infection and hepatocellular carcinoma: a systematic review. J Viral Hepat (2014) 0.99
Analysis of the viability of freezer stored serum samples for hepatitis C virus RNA analysis by the SUPERQUANT method: results of a 16 year retrospective study. J Virol Methods (1999) 0.99
Hepatitis Ain Greenland: importance of specific antibody testing in epidemiologic surveillance. Am J Epidemiol (1977) 0.99
Paediatric rhabdomyosarcoma of the ear and temporal bone. Clin Otolaryngol Allied Sci (2004) 0.99
Is there an optimal time to measure quantitative HCV RNA to predict non-response following interferon treatment for chronic HCV infection? J Hepatol (1998) 0.98
Application of a commercial kit for detection of PCR products to quantification of human immunodeficiency virus type 1 RNA and proviral DNA. J Clin Microbiol (1996) 0.98
Effect of rate-dependent left bundle branch block on global and regional left ventricular function. Circulation (1983) 0.97
Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum (2000) 0.97
Posttransfusion hepatitis type A. JAMA (1983) 0.97
Endocarditis and infections of intravascular devices due to Eikenella corrodens. Am J Med Sci (1986) 0.97
HLA-DR4 in ankylosing spondylitis with different patterns of joint involvement. Ann Rheum Dis (1985) 0.97
Normal immune response to hepatitis B vaccine in patients with Down's syndrome. A basis for immunization guidelines. JAMA (1985) 0.96
Microculture assay for isolation of human immunodeficiency virus type 1 and for titration of infected peripheral blood mononuclear cells. J Clin Microbiol (1990) 0.96
Alteration of hepatitis B antigen (HB Ag) determinants by reduction and alkylation. J Gen Virol (1973) 0.96
[Morphology of cavernous transformation of the portal vein (author's transl)]. Leber Magen Darm (1980) 0.95
Approaching the control of viral hepatitis type B. J Infect Dis (1976) 0.95